Skip to main content

Advertisement

Table 2 Characteristics of the studies included in this meta-analysis

From: Comparative efficacy of Chinese herbal injections for treating acute cerebral infarction: a network meta-analysis of randomized controlled trials

Study Acute phase Sex (M/F) Age Experimental group Control group Course Outcomes ADRs/ADEs
N T1 Dosage N T2 Dosage
Yu YC 2014 72 h 38/30 62.5 (44–76) 34 XST1 500 mg 34 AADN 14d (1) None
Yu YM 2009 72 h 71/45 62.5 (40–72) 58 DH 20 ml 58 FFDS 20 ml 15d (1)(2) Unclear
Yu Y 2015 72 h 35/21 54.3 (38–71) 28 XST1 500 mg 28 FFDS 20 ml 14d (1)(2) 6
Zhang ZJ 2008 74 h 41/30 64.3 35 SX 100 ml 36 FFDS 20 ml 14d (1) None
Zheng XD 2007 72 h 39/21 66.4 30 YXDM 20 mL 30 FFDS 30 ml 14d (1) None
Zhou SJ 2011 1 M 46/34 62 (42–75) 40 SX 100 ml 40 AADN 14d (1)(2) None
Zhou SF 2009 48 h 52/42 65.6 (62–86) 48 SX 200 ml 46 FFDS 20 mL 21d (1)(2) 10
Zhou SH 2013 72 h 50/40 62 45 SXN 20 ml 45 AADN 14d (1)(4) None
Xu XY 2011 12 h 40/20 55.9 (45–73) 30 YXDM 20 ml 30 DS 20 ml 21d (1)(2)(3) Unclear
Xie S 2011 24 h 42/30 61.4 (53–78) 36 SXT 6 ml 36 FFDS 20 ml 14d (1) None
Xie YG 2010 48 h 39/31 61.6 (50–76) 35 SXT 6 ml 35 DZHS 50 mg 14d (1)(2) None
Xu LL 2011 72 h 48/34 63.0 (55–81) 42 LI 120 mg 42 AADN 14d (1)(2) Unclear
Xu XQ 2012 72 h 64/44 57.9 54 YXDM 20 ml 54 FFDS 20 ml 14d (1)(2) 1
Yang HJ 2007 24 h 50/34 53.6 (39–75) 48 DSCXQ 10 ml 36 FFDS 10 ml 30d (1)(2) 1
Yang YF 2012 48 h 68 112 DH 30 ml 101 AADN 21d (1)(2) Unclear
Yao QY 2010 72 h 64/40 70.8 (54–82) 56 SXT 6 ml 48 LI 12 ml 14d (1)(2) 2
Yao J 2010 72 h 37/27 60.5 (49–76) 32 YXDM 20 ml 32 DZHS 50 mg 14d (1)(2) None
Xie RP 2010 72 h 52/28 42–80 40 SXN 20 ml 40 FFDS 20 mL 15d (1) None
Tan SY 2016 72 h 49/37 39–82 43 DH 30 ml 43 AADN 14d (1)(2) None
Wang WP 2015 72 h 49/41 68.2 (60–78) 45 SXN 20 mL 45 FFDS 20 mL 14d (1)(2) Unclear
Ren HM 2009 72 h 38/26 40–78 32 SX 100 ml 32 AADN 14d (1)(2) None
Sun HJ 2013 72 h 42/36 60.9 (40–70) 39 LI 120 mg 39 AADN 14d (1)(2) Unclear
Tang JP 2013 72 h 47/45 51.8 (43–73) 46 HHHSS 100 mg 46 AADN 14d (1)(2) None
Tang FY 2009 72 h 39/33 64.0 (50–78) 36 DZHS 50 mg 36 AADN 14d (1)(2) None
Tang XJ 2013 72 h 45/33 58 39 YXDM 20 mg 39 AADN 14d (1)(2) None
Wang L 2010 48 h 26/22 65.6 (62–86) 40 SX 200 mL 40 FFDS 20 mL 21d (1)(2) Unclear
Wang YL 2013 168 h 33/23 32–88 28 SXT 6 ml 28 DZHS 40 ml 14d (2) Unclear
Lan Y 2015 72 h 41/39 54–72 40 DSCXQ 10 ml 40 AADN 14d (1)(2) 3
Li M 2014 24 h 63/17 48–76 40 DH 30 ml 40 AADN 14d (2) Unclear
Liu YP 2010 72 h 45/35 51–71 40 DH 40 ml 40 AADN 15d (1) 1
Ma J 2010 24 h 29/31 59.1 (50–68) 30 DZHS 20 mg 30 AADN 14d (1)(2) Unclear
Ma J 2015 72 h 49/41 65.5 (45–79) 45 DH 20 ml 45 AADN 28d (1)(4) Unclear
Chen H 2015 24 h 74/60 59.4 (46–87) 67 SXT 6 ml 67 AADN 14d (1)(2) 5
Luan T 2014 48 h 52/43 57.5 50 XST2 0.4 g 45 DS 20 ml 15d (1)(4) 7
Huang ML 2012 72 h 158/142 62.6 (42–71) 150 XST1 500 mg 150 DS 25 ml 14d (1) 1
Li X 2015 72 h 129/71 62.9 100 HHHSS 0.1 g 100 AADN 14d (1)(2) Unclear
Ma ZL 2011 72 h 74/46 62.8 (45–84) 60 HHHSS 0.1 g 60 AADN 14d (1)(2) None
Zhang Y 2012 48 h 52/28 57.5 (35–80) 40 DSCXQ 100 mg 40 AADN 14d (1)(2) 1
Liu M 2014 48 h 79/57 60.2 (40–76) 68 DSCXQ 10 mL 68 AADN 14d (1)(2) 2
Chen YC 2011 72 h 44/24 57.9 34 YXDM 20 ml 34 FFDS 20 ml 14d (1)(2) 1
Yang RF 2013 48 h 52/48 60.8 (30–83) 50 SXT 6 g 50 AADN 14d (1) Unclear
Lin YF 2008 72 h 39/21 66.5 30 YXDM 20 ml 30 FFDS 20 ml 14d (1)(3) None
Peng T 2006 48 h 51/48 68 49 SXT 7 ml 50 FFDS 20 ml 14d (1)(3) 1
Li XH 2011 168 h 63.5(40–78) 120 SXN 20 ml 120 AADN 14d (1)(2) Unclear
Liu L 2015 6-72 h 74/46 61.4 (39–76) 60 DH 20 ml 60 SXN 20 ml 14d (1) None
Zhang YH 2010 6-72 h 62/34 58.9 (39–81) 48 DH 30 ml 48 XST2 400 mg 14d (1)(2) 5
Fan J 2006 72 h 56/32 64 (41–82) 44 YXDM 20 ml 44 FFDS 20 ml 14d (2) Unclear
Liu HY 2014 96 h 67/57 61.9 (38–83) 64 XST2 0.4 g 60 FFDS 30 ml 15d (1) None
Li FQ 2010 72 h 74/46 64 60 YXDM 30 ml 60 FFDS 40 ml 15d (1) Unclear
Lian CL 2013 360 h 49/43 62 (43–77) 46 LI 120 mg 46 AADN 30d (1) None
Chen S 2006 72 h 81/53 67.9 70 XST2 800 mg 64 XST1 10 ml 14d (1)(2) None
Cao LZ 2012 72 h 71/9 59.3 40 XST2 500 mg 40 FFDS 1.0 g 14d (1)(2) Unclear
Liu Y 2009 72 h 79/43 65.1 (43–73) 62 SXT 6 ml 60 XST2 8 ml 14d (1) 1
Luo XD 2011 72 h 35/25 61.8 30 XST2 0.4 g 30 AADN 14d (1)(2) 3
Liao MJ 2014 6-72 h 43/17 62.5 (36–80) 30 HHHSS 100 ml 30 XST2 400 mg 14d (1) Unclear
Shi JL 2010 72 h 51/33 62 42 YXDM 20 ml 42 LI 200 mg 30d (2) Unclear
Ni H 2010 24 h 61/55 62.7 (54–74) 59 SXN 20 ml 57 AADN 14d (1) Unclear
Li CP 2007 8-72 h 106/54 63.8 (42–85) 80 SXN 10-20 ml 80 AADN 14d (1) Unclear
Zhou ZP 2011 24 h 48/33 62.2 42 DZXX 30 ml 39 AADN 15d (1) Unclear
Chen C 2015 72 h 37/31 67.5 34 SXT 6 ml 34 XST2 400 mg 14d (1)(2) 14
Chen JY 2012 72 h 73/35 67 (40–76) 54 SXT 6 ml 54 FFDS 20 ml 14d (1)(2) Unclear
Luo QY 2007 72 h 54/36 63.6 (37–81) 45 SXN 6 ml 45 AADN 20 ml 14d (1) None
Chen J 2007 72 h 45/35 61 40 YXDM 20 ml 40 MLN 20 ml 15d (1)(2)(3) Unclear
Zhang XL 2005 6d 37/13 35–80 26 MLN 20 ml 24 FFDS 20 m l 21d (2) None
  1. M male, F female, AVG average, E experimental group, C control group, W week, D day, AADN aspirin + anticoagulants + dehydrant + neuroprotectant, DH Danhong injection + AADN, DS Danshen injection + AADN, DSCXQ Danshenchuangxiongqin injection + AADN, DZHS Dengzhanhuasu injection + AADN, DZXX Dengzhanxixin injection + AADN, FFDS Fufangdanshen injection + AADN, HHHSS Honghuahuangsesu injection + AADN, SX Shenxiong glucose injection + AADN, SXT Shuxuetong injection + AADN, XST1 Xueshuantong injection + AADN, XST2 Xuesetong injection + AADN, LI Ligustrazine injection + AADN, YXDM Yinxingdamo injection + AADN, SXN Shuxuening injection + AADN, MLN Mailuoning injection + AADN, ADRs adverse drug reactions, ADEs adverse drug events; (1): markedly effective rate; (2): neurological impairment; (3): death; (4): activities of daily living function; N: sample size; T1: therapy of experiment; T2: Therapy of control; N:Number of studies; −: No report